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neutrophil count  0.5109 /L was 14 and Median time of
platelet recovery 20109 /L was 25. At present 42 out of 52
are alive and 10 patients died due to acute GVHD, chronic
GVHD, rejection, veno-occlusive disease, infection and the
others. Thirty-four patients (64%) developed acute GVHD
(grade I  13, grade II  7, grade III 10, grade IV 4). Three
patients (5.8%) developed chronic GVHD (limited 2, exten-
sive 1). 8-year disease free survival were 73.17%. 8-year over-
all survival were 79.85%.
Conclusion: According to this study, for an acceptable out-
come in Thalassemia class 3We need better conditioning and
GVHD prophylaxis regimens to decrease cardiopulmonary and
liver complications. The results of blood and marrow transplan-
tation showed that it is better than supportive therapy such as
transfusion and desferal therapy.
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OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION FOR CHILDREN WITH ACUTE MYELOGENOUS LEUKEMIA IN
SECOND COMPLETE REMISSION, SINGLE CENTRE EXPERIENCE
Ishaqi, M.K.1, Afzal, S.1, Doyle, J.1, Gassas, A.1 1Division of Haema-
tology/Oncology/Bone Marrow Transplantation, Hospital for Sick Chil-
dren, University of Toronto, Canada, Toronto, ON, Canada.
Allogeneic hematopoietic stem cell transplantation (HSCT) is
proven to be an effective modality of treatment for children with
high risk or relapsed acute myelogenous leukemia (AML). Sur-
vival rate as high as 72% has been reported when offered to
patients in ﬁrst complete remission (CR1). The outcome for
children transplanted in second complete remission is less
favourable with reported survival ranging from 40 to 58%. We
reviewed 26 consecutive pediatric patients with AML who re-
ceived allogeneic HSCT in CR2 between 1994 and 2005 in the
Hospital for Sick Children, Toronto, Canada. Twenty-two pa-
tients transplanted in CR2 after chemotherapy only relapse and
4 patients suffered relapse after ﬁrst allogeneic transplant and
received second allogeneic HSCT in CR2. Conditioning regi-
mens included cyclophosphamide 50mg/kg infused over 1 hour
daily for 4 days and fractionated total body irradiation (TBI;
1200cGy) in six fractions over 3 days (CY/TBI) in 13 patients,
2 patients received Busulfan infused every 6 hours for 4 days
followed by cyclophosphamide 50mg/kg infused over 1 hour
daily for 4 days (Bu/CY), 5 patients received ATG in addition to
the Bu/CY regimen and 6 patients received other conditioning
regimens. Median age at transplant was 8.3 years (range 2.2-18.2
years). Four patients received matched sibling donor (MSD), 5
patients received one antigen mismatched related donor
(MMRD), 16 patients received unrelated donors and 1 patient
received unrelated cord progenitor stem cells. Primary graft
failure was encountered in 2 patients, 1 patient was re-trans-
planted successfully and remains alive in remission and the other
patient died of sepsis and respiratory failure. The rest of the
patients engrafted at a median of 20 days (range 10-35 days).
Acute grade III-IV and chronic GVHD occurred in 9 patients
(35%). Six patients (23%) suffered relapse, 4 of them died and
two are still alive at 2495 days and 2944 days with donor
leukocyte infusion (DLI) and second transplantation, respec-
tively. Six patients (23.0%) died from TRM. Including the 2
relapsed patients who were salvaged by DLI and a second
transplantation, survival was 62% with a median follow-up of
1198 days (range 53-4014 days). Conclusion: Survival for chil-
dren transplanted in CR2 for AML is higher than previously
reported, but relapse and treatment-related mortality remains a
concern.
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NOVEL TYROSINE KINASE INHIBITOR THERAPY (NTKI) PRIOR TO
ALLOGENEIC STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS
WITH CHRONIC MYELOID LEUKEMIA (CML): NO EVIDENCE FOR IN-
CREASED TRANSPLANT-RELATED TOXICITY
Jabbour, E.1, Cortes, J.1, Kantarjian, H.1, Giralt, S.1, Champlin, R.1,
de Lima, M.1 1University of Texas/MD Anderson Cancer Center,
Houston, TX.
Introduction: Patients undergoing ASCT for CML are increas-
ingly likely to have received a NTKI after failing imatinib mesy-
late. It is unknown whether the use of these NTKIs prior to ASCT
increases transplant-related toxicity.
Methods: We retrospectively analyzed the outcome of 12 pa-
tients with CML (1 chronic phase, 6 accelerated phase, and 5 in
blastic phase) who received dasatinib (n2), nilotinib (n7), or
both (n3) prior to ASCT.
Results: Median age was 41 years (range, 18-59 years). The
median time on treatment was 134 days (range, 30-285 days), and
the median time from the end of NTKI therapy to ASCT was 34
days (range, 7-130 days). Preparative regimen was ablative in 8
patients and non-ablative in 4. Source of stem cells were matched
related donors in 7 patients, matched unrelated in 3, haplo-iden-
tical in 1, and unrelated cord blood in 1. All patients engrafted
within 13 days. There was no signiﬁcant early transplant-related
toxicity: gastro-intestinal toxicities of grade 3 were encountered in
2 patients. One patient had secondary graft failure after 6 months
from the ﬁrst ASCT that required a second ASCT. Acute graft
versus host disease (GVHD) of grade 2 was observed in 7 patients
(58%), chronic GVHD in 6 (50%). Nine patients achieved a
molecular response: four complete and ﬁve major (Q-PCR
0.05%). Three patients had disease progression by day 30 post
ASCT. Two patients have relapsed after a median of 12 months
(range, 6-18 months). After a median follow-up of 10 months
(range, 3-22 months), 7 patients are alive in molecular response
and 5 patients died, 4 of disease progression and one of extensive
chronic GVHD.
Conclusion: Previous treatment with NTKI did not increase
transplant-related toxicity in this preliminary experience. Further
follow-up and larger number of patients will be necessary to con-
ﬁrm these observations.
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A MIND AND PHYSICAL FITNESS PROGRAM IN CANCER CARE – FEA-
SIBILITY OF A MULTIMODAL EXERCISE AND PSYCHO-EDUCATIONAL
INTERVENTION FOR PATIENTS UNDERGOING ALLOGENEIC STEM CELL
TRANSPLANTATION. A RANDOMIZED CONTROLLED PILOT STUDY
Jarden, M.1,3, Hovgaard, D.2, Boesen, E.3, Adamsen, L.1 1The Uni-
versity Hospitals Center for Nursing and Care Research, University
Hospital of Copenhagen, Copenhagen, Denmark; 2University Hospital of
Copenhagen, Department of Hematology, Copenhagen, Denmark;
3Danish Cancer Society, Copenhagen, Denmark.
Background: A pilot study incorporating a multimodal ﬁtness
and psycho-educational program to patients undergoing allogeneic
stem cell transplant (allo-HSCT). The main focus of the study is to
evaluate the feasibility, safety and effectiveness of a 4-6 week
intervention consisting of a ﬁtness program with progressive sta-
tionary bicycle-, muscle strength-, ﬂexibility- and relaxation train-
ing and a cognitive based supportive and educational intervention.
The aim of the study was to prevent or minimize loss of physical
capacity and improve overall well being during hospitalization.
Patients and methods: 20 adult patients (18 -65 years) were
randomized to either an intervention or control group using the
clinical international trial management system.Through triangula-
tion of qualitative and quantitative methods, patients are inter-
viewed, tested for physical capacity (VO2 max, muscle strength and
physical functioning), quality of life (EORTC, HADS, Fact-An
and Mini-mac) prior to admission and upon discharge. Patients
kept training journals and registered side effects during hospital-
ization. This study reports only the ﬁndings from the physical
capacity tests.
Results and Conclusion
Of the 22 eligible patients who met the eligibility criteria, 20
agreed to participate (90.9%).14 of 20 patients (70%) completed
all study requirements. In the intervention group, 6 of 9 patients
completed all study requirements (66.7% retention rate). Ad-
herence to the intervention showed that patients trained 94% of
the total expected training days. No adverse reactions or events
that can be attributed to either the testing or exercise program
were reported or observed. Pre test scores showed similiar
values in both groups for all physical capacity tests. Upon
Poster Session II 91
